Nice try but if you read the whole article you would see that the problem primarily lies in the quality of the manufactured drugs not necessarily the clinical trials. I would suggest peer reviewed nature of a2 trials will standup
- Forums
- ASX - By Stock
- A2M
- 2 new studies from A2MC
2 new studies from A2MC, page-28
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
|
|||||
Last
$5.58 |
Change
-0.060(1.06%) |
Mkt cap ! $4.058B |
Open | High | Low | Value | Volume |
$5.62 | $5.63 | $5.56 | $1.497M | 267.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 7039 | $5.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.58 | 666 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 6229 | 5.570 |
18 | 11464 | 5.560 |
11 | 37713 | 5.550 |
5 | 10676 | 5.540 |
6 | 41455 | 5.530 |
Price($) | Vol. | No. |
---|---|---|
5.580 | 666 | 3 |
5.590 | 15450 | 20 |
5.600 | 36103 | 17 |
5.610 | 16738 | 9 |
5.620 | 21545 | 6 |
Last trade - 12.26pm 12/09/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |